"Aspirin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
| Descriptor ID |
D001241
|
| MeSH Number(s) |
D02.455.426.559.389.657.410.595.176
|
| Concept/Terms |
Aspirin- Aspirin
- Acetylsalicylic Acid
- Acid, Acetylsalicylic
- 2-(Acetyloxy)benzoic Acid
|
Below are MeSH descriptors whose meaning is more general than "Aspirin".
Below are MeSH descriptors whose meaning is more specific than "Aspirin".
This graph shows the total number of publications written about "Aspirin" by people in this website by year, and whether "Aspirin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1995 | 1 | 0 | 1 |
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 2 | 2 |
| 2001 | 2 | 1 | 3 |
| 2002 | 1 | 1 | 2 |
| 2004 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 3 | 0 | 3 |
| 2007 | 2 | 0 | 2 |
| 2009 | 2 | 0 | 2 |
| 2010 | 1 | 1 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 2 | 3 | 5 |
| 2014 | 1 | 4 | 5 |
| 2015 | 2 | 1 | 3 |
| 2016 | 4 | 4 | 8 |
| 2017 | 4 | 1 | 5 |
| 2018 | 3 | 2 | 5 |
| 2019 | 6 | 3 | 9 |
| 2020 | 10 | 5 | 15 |
| 2021 | 1 | 3 | 4 |
| 2022 | 1 | 7 | 8 |
| 2023 | 0 | 4 | 4 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Aspirin" by people in Profiles.
-
Antiplatelet Therapy for Patients Who Have Undergone Revascularization Within the Past Year: Which Agents and for How Long? Med Clin North Am. 2024 May; 108(3):539-551.
-
Dyspnea-Related Ticagrelor Discontinuation After Percutaneous?Coronary Intervention. JACC Cardiovasc Interv. 2023 10 23; 16(20):2514-2524.
-
Bleeding and Ischemic Risks of Ticagrelor?Monotherapy After Coronary?Interventions. J Am Coll Cardiol. 2023 08 22; 82(8):687-700.
-
Efficacy and safety of P2Y12 inhibitor monotherapy after complex PCI: a collaborative systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2023 04 10; 9(3):240-250.
-
P2Y12 Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary Interventions. J Am Coll Cardiol. 2023 02 14; 81(6):537-552.
-
Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study. EuroIntervention. 2022 Dec 02; 18(11):e897-e909.
-
Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index. JACC Cardiovasc Interv. 2022 10 10; 15(19):1948-1960.
-
Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD. Eur Heart J Cardiovasc Pharmacother. 2022 Sep 29; 8(7):707-716.
-
Aspirin prophylaxis for hereditary and acquired thrombotic thrombocytopenic purpura? Am J Hematol. 2022 08; 97(8):E304-E306.
-
Deletion of platelet CLEC-2 decreases GPIba-mediated integrin aIIbß3 activation and decreases thrombosis in TTP. Blood. 2022 04 21; 139(16):2523-2533.